97211 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
Trispecific T cell Engagers
#2TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS
#3TUMOR-TARGETED SPLIT IL2 RECEPTOR AGONISTS
#4ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF
#5Cysteine Engineered Antibodies and Conjugates
#6ANTI-sCD146 ANTIBODIES AND USES THEREOF
#7ANTIBODIES AGAINST MUC1 AND METHODS OF USE THEREOF
#8Colon and Pancreas Cancer Peptidomimetics
#9BISPECIFIC, MODULATABLE ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF
#10IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
#11CLICK-TO-RELEASE ON PROTEINS AND PEPTIDES
#12Bispecific Molecule Stabilizing Composition
#13MULTISPECIFIC CONSTRUCTS AND USES THEREOF
#14ONCOLYTIC VIRUS EXPRESSING AN IMMUNE CELL ENGAGER FOR TUMOR TARGETING
#15BISPECIFIC T CELL ENGAGERS
#16DEGRADATION OF cMET USING A BISPECIFIC BINDING AGENT
#17DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#18POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION
#19DEGRADATION OF EGFR USING A BISPECIFIC BINDING AGENT
#20IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
#21MUC1 Antibodies and Methods of Use
#22CD146 AND USES THEREOF AS A BIOMARKER AND AS A THERAPEUTIC TARGET IN THE DIAGNOSIS AND TREATMENT OF FIBROSIS
#23ANTIBODIES SPECIFIC TO MUC18
#24ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#25TUMOR-TARGETED SPLIT IL12 RECEPTOR AGONISTS
#26GENETICALLY MODIFIED CELLS AND USES THEREOF
#27FUSION CONSTRUCTS AND METHODS OF USING THEREOF
#28ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
#29NKG2D EXPRESSING CAR-T CELLS
#30ANTI-MUC17 NANOBODY AND USE THEREOF
#31POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF
#32CHIMERIC ANTIGEN RECEPTOR AND IL-18 RECEPTOR COMPOSITIONS AND METHODS OF USE THEREIN
#33ANTI-MUC1 ANTIBODY
#34ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF
#35ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
#36ANTI-CANAG ANTIBODY CONJUGATE
#37METHODS OF TREATING CANCER AND MONITORING CANCER PROGRESSION
#38ANTIBODY CONJUGATES SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF
#39Chimeric Antigen Receptor Therapies and Vasoactive Intestinal Peptide Receptor Antagonists
#40SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#41NOVEL ANTI-MUC1 ANTIBODY AND USE THEREOF
#42ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF
#43AFFINITY-ENHANCED MONMERIC STREPTAVIDIN CHIMERIC ANTIGEN RECEPTOR (CAR)
#44ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF
#45METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
#46ANTIBODY SPECIFICALLY BINDING TO MUC-1 AND USES THEREOF
#47ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES
#48ANTIBODY AND USE THEREOF
#49MUC16 CHIMERIC ANTIGEN RECEPTORS
#50MUC1 and CD16A Antibodies and Methods of Use
#51ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
#52DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
#53USE OF OREGOVOMAB AND PARP INHIBITORS FOR TREATMENT OF OVARIAN CANCER
#54HIGH-EFFICIENCY, CONDITIONALLY-ACTIVATED ANTIBODY DISCOVERY AND MASKED ANTIBODIES
#55SINGLE CHAIN CONSTRUCTS
#56USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION
#57HUMANIZED MUC1 ANTIBODY AND ANTIBODY DRUG CONJUGATE
#58MULTICISTRONIC CHIMERIC PROTEIN EXPRESSION SYSTEMS
#59ANTIGEN-BINDING DOMAINS AND METHODS OF USE THEREOF
#60HUMANIZED ANTI-MUC1* ANTIBODIES
#61ANTI-CANCER PEPTIDE
#62MULTI-SPECIFIC LIGAND BINDERS
#63PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEX
#64Trispecific T cell Engagers
#65CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES
#66Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
#67ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF
#68Method for making pluripotent stem cells
#69MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#70FUSION PROTEINS AND USES THEREOF
#71SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#72DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
#73FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
#74Bispecific T cell Engagers
#75METHOD OF RECONSTITUTING LYOPHILIZED FORMULATION
#76CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS
#77Combotope Antibody Libraries
#78HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME
#79NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTS
#80NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#81CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER
#82MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ED)
#83ANTI-MUC16 ANTIBODIES
#84Chimeric antigen receptor compositions and methods for treating MUC1* diseases
#85DUAL EGFR-MUCI CHIMERIC CANTIGEN RECEPTOR T CELLS
#86Cysteine Engineered Antibodies and Conjugates
#87MUTATED FERRITIN PROTEIN
#88NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY
#89PSG1 FOR USE IN THE TREATMENT OF OSTEOARTHRITIS
#90ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES
#91SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION
#92THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#93METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS
#94METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)
#95COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#96HUMAN ANTIBODIES TO TN ANTIGEN
#97COMPOSITIONS AND METHODS FOR MUC18 TARGETING
#98COMBINATION TREATMENT
#99ANTI-TN-MUC1 CHIMERIC ANTIGEN RECEPTORS
#100Anti-MUC1 antibody-drug conjugate
#101CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#102Glycan-Interacting Compounds and Methods of Use
#103Compositions and Methods for Treating Cancer
#104BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING EGFR AND MUC1 AND USES THEREOF
#105MUC1* ANTIBODIES
#106T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#107PD-1 mutant polypeptide and preparation and application thereof
#108Humanized anti-MUC1* antibodies
#109Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
#110Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
#111Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
#112ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#113METABOLISM-BASED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF TREATMENT
#114BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1
#115AEROSOLIZED MUCUS-TETHERING NANOBODIES TO PROTECT AGAINST VIRAL AND MICROBIAL CONTAMINATION IN CLOSED AND SEMI-ENCLOSED SPACES
#116Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells
#117Humanized anti-MUC1* antibodies
#118COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA
#119Anti-MUC1 antibody-drug conjugate
#120Cysteine Engineered Antibodies and Conjugates
#121DIAGNOSTIC ANTIBODIES AGAINST MUCIN 17 AND USES THEREOF
#122RI-LABELED HUMANIZED ANTIBODY
#123Antibody binding specifically to MUC1 and use thereof
#124ANTI- MUC1-SEA ANTIBODIES
#125ANTI-MUC1 COMPOSITIONS AND METHODS OF USE
#126COMPOSITIONS AND METHODS FOR GAMMA DELTA TCR REPROGRAMMING USING FUSION PROTEINS
#127METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#128USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
#129Antibody binding specifically to MUC1 and use thereof
#130ANTI-MUC16 ANTIBODIES AND USES THEREOF
#131Splicing modulator antibody-drug conjugates and methods of use
#132COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#133NOVEL RECEPTORS HAVING A FIBRONECTIN REPEAT FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION
#134GENETICALLY MODIFIED CELLS AND USES THEREOF
#135ANTI-CANCER PEPTIDE
#136ANTIBODIES AGAINST MUC1 AND METHODS OF USE THEREOF
#137ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
#138IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
#139Glycan-Interacting Compounds and Methods of Use
#140COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER
#141IMMUNE CELLS EXPRESSING MODIFIED CELL RECEPTORS AND METHODS OF MAKING
#142HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#143AFFINITY MATURATED TAG72 SPECIFIC SINGLE CHAING ANTIBODIES
#144NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#145Expression Process
#146THERAPEUTIC ANTIBODIES FOR TREATING LUNG CANCER
#147GENETICALLY MODIFIED IMMUNE CELL, PREPARATION METHOD THEREFOR, AND APPLICATION
#148Antibodies specific to glycosylated PD-L1 and methods of use thereof
#149MUC16 specific chimeric antigen receptors and uses thereof
#150MUC16 specific chimeric antigen receptors and uses thereof
#151MODULATORS OF CELL SURFACE PROTEIN INTERACTIONS AND METHODS AND COMPOSITIONS RELATED TO SAME
#152CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE
#153NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#154Anti-glyco-MUC1 antibodies and their uses
#155CORE3-MUC1 binding polypeptides and uses thereof
#156NOVEL POLYPEPTIDES
#157ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#158SINGLE CHAIN CONSTRUCTS
#159ANTIBODIES SPECIFIC TO MUC18
#160ANTIBODIES SPECIFIC TO MUC18
#161Methods, arrays and uses thereof
#162Fusion constructs and methods of using thereof
#163CD146 AND USES THEREOF AS A BIOMARKER AND AS A THERAPEUTIC TARGET IN THE DIAGNOSIS AND TREATMENT OF FIBROSIS
#164Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
#165ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
#166Colon and Pancreas Cancer Peptidomimetics
#167COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
#168THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#169Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
#170Compositions and methods for stabilizing protein-containing formulations
#171IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
#172Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
#173Ri-labeled humanized antibody
#174MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE
#175Compositions and methods of treating cancer with chimeric antigen receptors
#176COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS
#177Antibodies to MUC16 and methods of use thereof
#178TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
#179Splicing modulator antibody-drug conjugates and methods of use
#180Anti-glyco-MUC1 antibodies and their uses
#181Trispecific T cell engagers
#182METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
#183COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#184Bispecific T cell engagers
#185Antibodies useful for detection of human carcinoma antigen
#186Anti-MUC1 antibody
#187ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
#188ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
#189PODOPLANIN POSITIVE MACROPHAGES
#190Peptide-based compounds for use in the prevention, treatment and/or detection of cancer
#191Bispecific antibody construct directed to MUC17 and CD3
#192Antibody binding specifically to MUC1 and use thereof
#193Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
#194Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
#195MUC16 monoclonal antibody and uses thereof
#196Splicing modulator antibody-drug conjugates and methods of use
#197HUMAN ANTIBODIES THAT BIND AND ARE INTERNALIZED BY MESOTHELIOMA AND OTHER CANCER CELLS
#198T cell disease treatment targeting TAG-72
#199Multi-specific ligand binders
#200Method for making pluripotent stem cells
#201L2A5 antibody or functional fragment thereof against tumour antigens
#202Diagnostic methods using anti-MUC1* antibodies
#203METHOD FOR ANTI-MUC1* CAR T CELL STIMULATION
#204Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
#205HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME
#206PROLIFERATION OF MUC1 EXPRESSING CELLS
#207Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
#208Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-like Protein (MLP) as a Biomarker for Ovarian and Pancreatic Cancer
#209BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#210Cysteine engineered antibodies and conjugates
#211Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
#212Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#213Immunoconjugates with an intracellularly-cleavable linkage
#214CD1d and TCR-NKT Cells
#215Anti-CD146 antibodies and uses thereof
#216Anti-human MUC1 antibody Fab fragment
#217Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#218COMPOSITIONS AND METHODS FOR TREATING CANCER
#219MUC1* antibodies
#220Anti-MCAM Antibodies And Associated Methods Of Use
#221METHOD OF INDIRECT IMMUNIZATION OF HUMAN OVARIAN CANCER PATIENTS THROUGH SELECTION OF XENOGENEIC IMMUNOGLOBULIN FC PORTIONS
#222Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
#223NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT
#224MCAM ANTAGONISTS AND METHODS OF TREATMENT
#225Colon and pancreas cancer peptidomimetics
#226Peptidomimetic compounds and antibody-drug conjugates thereof
#227Oncolytic viral delivery of therapeutic polypeptides
#228PD-L1 AND TA-MUC1 ANTIBODIES
#229MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
#230Immunoconjugates with an intracellularly-cleavable linkage
#231Monoclonal and humanized antibodies to a cancer glycopeptide
#232Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
#233METHOD OF INDIRECT IMMUNIZATION OF HUMAN OVARIAN CANCER PATIENTS THROUGH SELECTION OF XENOGENEIC IMMUNOGLOBULIN FC PORTIONS
#234IgE antibodies for the inhibition of tumor metastasis
#235Immune cells expressing engineered antigen receptors
#236ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
#237NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTS
#238Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
#239METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#240Antibody binding specifically to MUC1 and use thereof
#241CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
#242CHIMERIC ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
#243ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
#244Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
#245Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#246MUC16 specific chimeric antigen receptors and uses thereof
#247USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
#248CHIMERIC ANTIGEN RECEPTORS (CARS) SPECIFIC FOR MUC1 AND METHODS FOR THEIR USE
#249TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER
#250Affinity maturated TAG72 specific single chain antibodies
#251Anti-human MUC1 antibody Fab fragment
#252HUMANIZED ANTI-MUC1* ANTIBODIES AND USE OF CLEAVAGE ENZYME
#253TAG-72-binding chimeric antigen receptors
#254Bispecific antibody and antibody conjugate for tumor therapy and use thereof
#255Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
#256Anti-human MUC1 antibody fab fragment
#257Antibodies useful for detection of human carcinoma antigen
#258Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#259Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
#260Synthetic lipopeptide vaccines and immunotherapeutics
#261Compositions and methods for stabilizing protein-containing formulations
#262Modified cell expansion and uses thereof
#263METHODS FOR TREATMENT OF OVARIAN CANCER
#264ANTI-OSTEOSARCOMA CAR-T DERIVED FROM THE ANTIBODY OI-3
#265Immunoconjugates with an intracellularly-cleavable linkage
#266Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
#267Anti-glyco-MUC1 antibodies and their uses
#268Human antibodies to Tn antigen
#269Tn-MUC4 binding polypeptides and uses thereof
#270Antigen responsive antibody-fluorescent dye conjugate and method for fluorescence detection and imaging of target cell using the same
#271Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#272Antibody binding to HEG1 and use of the antibody for detection and treatment of mesothelioma
#273Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
#274Oncolytic viral delivery of therapeutic polypeptides
#275Method of treating an NME7 expressing cancer with a peptide
#276ANTI-NME ANTIBODY
#277Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#278IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
#279Multi-specific binding conjugate, related pharmaceutical compositions and use
#280Genetically modified cells and uses thereof
#281COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#282Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
#283Glycan-interacting compounds and methods of use
#284Immunoconjugates with an intracellularly-cleavable linkage
#285Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#286CERVICAL CANCER TESTING METHOD AND TEST REAGENT USED THEREFOR
#287Anti-MUC18 human immunotoxin and applications thereof
#288METHOD OF STEM CELL-BASED ORGAN AND TISSUE GENERATION
#289Antibodies to MUC16 and methods of use thereof
#290Antibodies to endoplasmin and their use
#291MUC1* antibodies
#292Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
#293TREATMENT OF CANCER WITH THERAPEUTIC MONOCLONAL ANTIBODY SPECIFIC FOR A TUMOR ASSOCIATED ANTIGEN AND AN IMMUNE ADJUVANT
#294Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
#295ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
#296COMPOSITIONS COMPRISING CHIMERIC ANTIGEN RECEPTORS, T CELLS COMPRISING THE SAME, AND METHODS OF USING THE SAME
#297Human monoclonal antibodies specific for glypican-3 and use thereof
#298Expression process
#299CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the Same
#300Anti-MUC16 antibodies